Cryopreservation protocols optimized for T cells kill ~75% of NK cells w/in 24 h of thaw due to leakage of GzmB from vesicles. This is prevented by IL15/IL-18 pretreatment to ⬆️antiapoptotic genes & deplete gzmB containing granules [Berjis & Sheppard]
nature.com/articles/s4146…

🚗 Back to the big CARs - a macrophage (get it - 'macro') CAR active against PANC bit.ly/3ygrefr

Superstar Dr. Kristin Anderson, PhD UVAimmunology reviews how #TCRTcells are used to target tumor associated and tumor specific antigens with no CRS AAI Society for Immunotherapy of Cancer Monitoring for autoimmunity is critical! #AAI2024

Superstar Daniel Powell Lab @ UPENN Penn Medicine reviews how vaccine-induced T cells from peptides and tumor lysate pulsed DCs have activity vs #melanoma #ovariancancer Adding NSAIDs and IL2 improves responses AAI Society for Immunotherapy of Cancer #AAI2024

First up AAI Society for Immunotherapy of Cancer symposium! Rockstar Brian Gastman, MD Iovance Biotherapeutics reviews how #TILs are beneficial in #melanoma Specific CD8 TIL subsets support effector and resident memory responses #AAI2024

Safety and anti-tumor activity of autologous Her2 CART in sarcoma. Congratulations Nabil, Meena and the extended team Center for Cell and Gene Therapy and beyond
nature.com/articles/s4301…

The U.S. FDA has approved lutetium Lu 177 dotatate for pediatric patients 12 years of age and older with SSTR–positive GEP-NETs. #oncology onclive.com/view/fda-appro…

#Breakingnews : In a MAJOR step forward, the FDA has approved the first targeted treatment for pediatric pLGG, the most common pediatric brain cancer.

Congratulations, Day One Biopharmaceuticals and Sam Blackman, Day One Founder and a member of our Board of Directors!

lnkd.in/ebsWFpNa

Also great to see the thalassemia data for exa-cel.

Super excited to see the exa-cel (Casgevy) #SickleCellDisease results out today in NEJM. These are the data that led to FDA approval Dec23 (during #ash2023 ). Terrific study steering committee. More data to come in younger pts. Now to work on access! Vertex Pharmaceuticals Cancer Center @ CHOP

Rockstar pediatric hematologist Matthew Porteus Stanford Medicine reviews usage of CRISPR/Cas9 to edit HSCs to correct beta-globin and RAG2 as a treatment for #sicklecelldisease and #SCID UW SCRMC BTC Institute Also knockouts CCR5 while knocking-in neutralizing antibody to treat #HIV

Superstar Marian Dam Moffitt Cancer Center discusses coordinating aspects of #TIL therapy #melanoma and protocol based obstacles Society for Immunotherapy of Cancer The process from tumor excision, LD chemo, infusion and IL2 admin is complex #LearnACI

Superstar Bonnie Yates NCI CCR Pediatric Oncology Branch reviews diagnosis and management of common #CARTcell toxicities like CRS, ICANS and HLH Society for Immunotherapy of Cancer Importantly not all CD19 CAR products are equal, and toxicity will vary based on the CAR design, age, diagnosis and disease burden #LearnACI

Rising star Raj Chakraborty Herbert Irving Comprehensive Cancer Center discusses use of T cell engagers for #myeloma Society for Immunotherapy of Cancer While single agent efficacy is high (up to 70%), infections are still an issue (up to 40%) in part from prior chemotherapy. CRS/ICANS is typically rare. #LearnACI

Rockstar Ecaterina Dumbrava MD Anderson Cancer Center reviews #TCRTcells for solid tumors like #sarcoma #pancreaticcancer Society for Immunotherapy of Cancer MAGE-A4 is under priority review for FDA approval with NY-ESO1 and KRASG12D in clinical trials. Even #TCRNKcells are emerging! #LearnACI

Superstar Amod Sarnaik Moffitt Cancer Center discusses the logistics in generating and administering lifileucel and #TILs for #melanoma Society for Immunotherapy of Cancer Can be a useful therapy in patients who do not respond to anti-PD1, with some responses ongoing for years #LearnACI